skip to main content
Back to all blog posts

Posted in: Intellectual Property

May 15, 2018

Certificates of Supplementary Protection for Canadian Pharmaceutical Patents

By Kitt Sinden, M.Sc.

Patents granted in Canada have typically carried a 20-year term of protection from the date of filing, regardless of the time taken to be examined and granted by the Patent Office or for the underlying products to be approved by regulatory agencies. However, since September 2017, as part of concessions made during the negotiations for the Canada-European Union Comprehensive Economic and Trade Agreement, amendments to the Canadian Patent Act and the implementation of the Certificate of Supplementary Protection Regulations (Regulations) now provide for Certificates of Supplementary Protection (CSP). Canadian CSPs effectively extend the term of some patents directed to medicinal ingredients, or combinations of medicinal ingredients, contained in drug products for human and veterinary use, which products have experienced delays in regulatory approval.

The issuance of a CSP grants the certificate’s holder and their legal representatives the same legal rights, privileges and liberties that are granted by the patent set out in the certificate, but only with respect to the making, constructing, using and selling (but not for the purposes of exporting) of any drug product that contains the medicinal ingredient, or combination of medicinal ingredients.

The term of the supplementary protection is a maximum of two years, based on the date of authorization for sale of the drug product, but it may be discounted by any period of unjustified delay caused by the Applicant’s failure to act.

A list of CSP applications and their status is available on the Health Canada website and information regarding the patents to which the CSP applications relate is available on the Canadian Intellectual Property Office website.

Currently, thirteen CSP applications for human use have been filed since the Regulations came into force in September 2017. Out of the thirteen applications, four have been issued, providing the maximum of two years of extended protection, while one application has been refused, presumably on the basis that the subject patent relates to a single medicinal ingredient, whereas the underlying drug product contains a combination of medicinal ingredients.

The issuance of Canadian CSPs is great news for pharmaceutical patentees looking to recoup some of the patent term lost to delays in regulatory approval of their drug products. However, there are important eligibility requirements and filing deadlines for any CSP application based on the subject matter of the patent and the timing of its grant and the underlying drug product and the timing of its market approval in Canada and in other jurisdictions. Contact us for assistance in navigating these new Regulations.

Areas of Expertise

Related Categories

Related Blogs

Posted in: Intellectual Property | Blockchain

Insights TheSpotlight
The Ultimate Blockchain Patent Teardown Why blockchain applications are patent-eligible By Tony Sabeta, B.Eng. Aug 15, 2018 As a patent practitioner, one of the questions I often get asked is whether distributed ledger technology (DLT), such as blockchain, is patentable. I naturally respond in the affirmative (with some qualifiers of course), and inevitably there is a deluge of follow-up questions and statements such...

Posted in: Intellectual Property | Court Decision

Insights TheSpotlight
The Value of a Copyrighted Photograph Is Not Necessarily in the Eye of the Beholder By Ken Clark and Stan Fedun Jul 19, 2018 In the May 2018 decision, Gaudreau c Néomédia inc., the Québec Small Claims Court considered the amount of damages to award for the unauthorized use of a copyrighted photograph.

Posted in: Intellectual Property

Insights TheSpotlight
Quebec Court Denies Exclusive Use Of Geographic Location in Car Dealership’s Name By Stan Fedun and Ken Clark Jun 18, 2018 In the recent Superior Court of Quebec decision, 7531877 Canada ltée (Buckingham Chrysler, Jeep, Dodge) c 9531025 Canada Inc. (Buckingham Chevrolet Buick GMC), dated May 17, 2018, the plaintiff alleged that the defendant engaged in false advertising (name appropriation) by using “Buckingham” in i...